文献速递甲状腺核医学核素与放射性配体治疗

甲状腺切除术后快速通道放射性碘消融治疗可减少分化型甲状腺癌患者病假(FASTHYNA 试验)

Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial).
PubMed 文献 · Clin Nucl Med · 2019-01-01

FASTHYNA 随机多中心试验纳入接受全切或补全甲状腺切除、有至少每周12小时带薪工作的 T1-3 N0-1 M0-x 分化型甲状腺癌患者,比较术后1周快速通道与标准方案 RhTSH 辅助放射性碘消融治疗。结果显示快速通道组病假时长和生产力损失相关费用显著低于标准治疗组,生活质量无显著差异。

要点

  • 快速通道组平均病假时长显著低于标准治疗组(115 vs 280 小时,P=0.02)。
  • 快速通道组生产力损失相关费用显著低于标准治疗组(4070.77 vs 9202.90 欧元,P=0.02)。
  • 两组生活质量无显著差异。

核心结论

  • 快速通道组病假时长和社会成本显著降低,且生活质量未恶化,因此快速通道消融是可取的。

研究设计与样本

  • 随机、多中心试验,纳入分型为 T1-3 N0-1 M0-x 且接受全切或补全甲状腺切除、有至少每周12小时带薪工作的分化型甲状腺癌患者。
  • 主要终点为自手术之日起报告的病假天数,次要终点为生活质量和缺勤相关的社会成本。
  • 2013年11月至2016年5月期间有20例患者符合纳入条件。

主要发现

  • 快速通道组与标准治疗组平均病假时长分别为115小时和280小时,差异显著(P=0.02)。
  • 快速通道组与标准治疗组生产力损失相关费用分别为4070.77欧元和9202.90欧元,差异显著(P=0.02)。
  • 两组生活质量无显著差异。

临床怎么用

  • 对于符合条件的分化型甲状腺癌术后患者,可考虑术后1周快速通道 RhTSH 辅助放射性碘消融治疗以减少病假和社会成本。

局限性

  • 2013年11月至2016年5月期间仅20例患者符合纳入条件,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant human thyroid stimulating hormone (RhTSH) aided radioiodine ablative therapy (RIT) is current-day practice in the treatment of differentiated thyroid cancer (DTC). It is often planned 4 to 6 weeks after surgery or sometimes even longer (standard protocol). The RhTSH-aided RIT, however, has the advantage that it can be planned shortly after thyroidectomy. The FASTHYNA trial was designed to test the hypothesis that RIT 1 week after thyroidectomy (fast-track protocol) results in a significant reduction of sick leave with lower societal costs and with a better quality of life (QOL) compared with the current standard treatment. METHODS: In a randomized, multicenter trial, we included patients with differentiated thyroid cancer, stage T1-3 N0-1 M0-x, who were treated with a total or completion thyroidectomy, with a paid job of at least 12 hours per week. The primary study end point was days of sick leave reported from time of surgery. Secondary end points were QOL and societal costs associated with absence from work. RESULTS: Twenty patients were eligible for inclusion between November 2013 and May 2016. Significant decreases in mean duration of sick leave in the fast-track group versus the standard care group (115 and 280 hours, respectively, P = 0.02) and in costs associated with productivity losses (&OV0556;4070.77 vs &OV0556;9202.90, P = 0.02) were found. There were no significant differences in QOL between both groups. CONCLUSIONS: The trial showed a significant reduction in sick leave and in societal costs in the fast-track group without a deterioration of QOL. Therefore, fast-track ablation is desirable. TRIAL REGISTRATION: Netherlands trial register: NTR 3933.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Waissi F, Kist JW, Lodewijk L, et al. Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). Clin Nucl Med. 2019. PMID: 30562195. doi:10.1097/RLU.0000000000002420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。